Compare · ADSEW vs EW
ADSEW vs EW
Side-by-side comparison of ADS-TEC ENERGY PLC Warrant (ADSEW) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- ADSEW operates in Consumer Discretionary, while EW operates in Health Care - the two are in different parts of the market.
- EW is the larger of the two at $48.52B, about 1391.8x ADSEW ($34.9M).
- Over the past year, ADSEW is down 76.1% and EW is up 11.4% - EW leads by 87.4 points.
- EW has been more active in the news (5 items in the past 4 weeks vs 3 for ADSEW).
- EW has more recent analyst coverage (25 ratings vs 0 for ADSEW).
- Company
- ADS-TEC ENERGY PLC Warrant
- Edwards Lifesciences Corporation
- Price
- $0.50-30.56%
- $84.16+5.54%
- Market cap
- $34.9M
- $48.52B
- 1M return
- -30.56%
- +1.83%
- 1Y return
- -76.08%
- +11.37%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 5
- Recent ratings
- 0
- 25
ADS-TEC ENERGY PLC Warrant
ADS-TEC Energy PLC, a B2B technology company, develops, manufactures, and services intelligent battery buffered energy systems. The company offers ChargeBox, a battery storage system that integrates inverter, climate control, energy management, security/firewall, and communication units; and ChargeTrailer, a mobile high power charging system in the form of a truck trailer. It also provides PowerBooster, a battery system that delivers high levels of power for the charging process; Storage Rack System, a scalable battery system; and Storage Container System, a custom battery system for large-scale applications as 20- or 40-foot container solutions. The company was founded in 1980 and is based in Dublin, Ireland.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest ADSEW
- Amendment: SEC Form 6-K/A filed by ADS-TEC ENERGY PLC Warrant
- Amendment: SEC Form 6-K/A filed by ADS-TEC ENERGY PLC Warrant
- SEC Form 6-K filed by ADS-TEC ENERGY PLC Warrant
- SEC Form 3 filed by new insider Fabritius Andreas
- Amendment: SEC Form 3 filed by new insider Rudloff Michael
- SEC Form 3 filed by new insider Schypulla Sebastian
- SEC Form 3 filed by new insider Speidel Thomas
- SEC Form 3 filed by new insider Epple Alwin
- SEC Form 3 filed by new insider Rudloff Michael
- SEC Form 3 filed by new insider Lauk Kurt J
Latest EW
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports First Quarter Results
- Edwards Lifesciences to Host Earnings Conference Call on April 23, 2026
- SEC Form 4 filed by Ullem Scott B.
- SEC Form 4 filed by Lippis Daniel J.
- SEC Form 4 filed by Bobo Donald E Jr
- Edwards Lifesciences upgraded by Wolfe Research with a new price target
- Two Year Data on Edwards Lifesciences' EVOQUE System Continue to Demonstrate Significant and Sustained Patient Benefits
- Amendment: SEC Form SCHEDULE 13G/A filed by Edwards Lifesciences Corporation
- SEC Form DEFA14A filed by Edwards Lifesciences Corporation